Warner-lambert Company

Amgen Fremont Inc.

Millennium Pharmaceuticals Limited

Abgenix, Inc.

Joseph Edwin Low

Madhav Narasimha Devalaraja

Ian Nevin Foltz

Mary Haak-Frendscho

Vahe Bedian

James Leslie Mobley

Sirid-Aimee Kellermann

Sirid-Aimée Kellermann

David T Connor

Bruce D Roth

Jay R Luly

Bharat Kalidas Trivedi

Kenneth Gordon Carson

Steven Robert Miller

Vijaykumar M Baragi

Vaishalee A Padgaonkar

Jie Jack Li

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

Antibodies to M-CSF

Nucleic acid molecules encoding antibodies to M-CSF

Methods of treating arthritic conditions with antibodies to M-CSF

A hematopoetic factor called 'colony stimulating factor' (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and/or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

Methods of treating inflammation using antibodies to M-CSF

The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor.

Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor

Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

Substituted quinoxaline derivatives as interleukin-8 receptor antagonists

Tetrazol-benzothiophenes carboxamides or a pharmaceutically acceptable salt thereof are useful in preventing ulcer formation caused by nonsteroidal antiinflammatory drugs in mammals.

Method of preventing ulcer formation caused by nonsteroidal

Growing community of inventors

Ann Arbor, MI, United States of America

Joseph Edwin Low